监事会认为董事会编制和审核公司《2025 年第三季度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 证券代码：002099 证券简称：海翔药业 公告编号：2025-044 浙江海翔药业股份有限公司 第七届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届监事会第十次会议 于 2025 年 10 月 23 日以电子邮件形式发出通知，于 2025 年 10 月 27 日以通讯表 决的方式召开，会议应参加表决监事 3 人，实际参加表决监事 3 人。会议召开符 合《公司法》及《公司章程》的规定，合法有效。会议由监事会主席陈敏杰先生 主持，经过与会监事的充分讨论，会议审议通过了如下议案： 一、审议通过了《2025 年第三季度报告》 特此公告。 浙江海翔药业股份有限公司 监 事 会 二零二五年十月二十九日 表决结果：同意 3 票，反对 0 票，弃权 0 票 内容详见巨潮资讯网及 2025 年 10 月 ...

证券代码：002099 证券简称：海翔药业 公告编号：2025-043 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 内容详见巨潮资讯网及 2025 年 10 月 29 日《证券时报》《证券日报》刊登 的《2025 年第三季度报告》（公告编号：2025-045）。 二、审议通过了《关于公司董事会换届选举非独立董事的议案》 本议案已经公司董事会提名委员会审议通过。 浙江海翔药业股份有限公司 第七届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第十六次会 议于 2025 年 10 月 23 日以电子邮件形式发出通知，于 2025 年 10 月 27 日以通讯 表决的方式召开，会议应参加表决董事 7 人，实际参加表决董事 7 人。会议召开 符合《公司法》及《公司章程》的规定，合法有效。会议由董事长王扬超先生主 持，经过与会董事的充分讨论，会议审议通过了如下议案： 一、审议通过了《2025 年第三季度报告》 本议案已经公司董事会审计委员会审议通过。 表决结果：同意票 7 ...

关于浙江海翔药业股份有限公司 部分募投项目延期的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 浙江海翔药业股份有限公司（以下简称"海翔药业"或"公司"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号 ——保荐业务》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等相关规定，对海翔药业部分募投项目延期事项进行了核查，具体 情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2016〕765 号文核准，并经深圳证券 交易所同意，海翔药业由主承销商国泰海通证券股份有限公司采用非公开发行方 式，向特定对象非公开发行人民币普通股（A 股）股票 99,890,023 股，发行价为 每股人民币 10.28 元，共计募集资金 1,026,869,436.44 元，坐扣承销费和保荐费 等 10,000,000.00 元（含税）后的募集资金为 1,016,869,436.44 元，已由主承销商 国泰海通证券股份有限公司于 2016 年 9 月 ...

浙江海翔药业股份有限公司 2025 年第三季度报告 浙江海翔药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 证券代码：002099 证券简称：海翔药业 公告编号：2025-045 □是 否 | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损益（包 | | | | | 括已计提资产减值准备的冲 | 245,756.88 | 44,322.98 | | | 销部分） | | | | | 计入当期损益的政府补助 | | | | | （与公司正常经营业务密切 | | | | | 相关、符合国家政策规定、 | 190,806. ...

Core Insights - Haisheng Pharmaceutical reported that as of October 20, the number of its shareholders reached 27,682 [2] Company Summary - The company actively engages with investors through interactive platforms, indicating a commitment to transparency and communication [2] - The increase in shareholder numbers may reflect growing interest in the company's stock and potential market performance [2] Industry Context - The pharmaceutical industry continues to attract investors, as evidenced by the increasing number of shareholders in companies like Haisheng Pharmaceutical [2] - Engagement with investors is crucial in the pharmaceutical sector, where market dynamics can significantly impact company valuations [2]

Market Overview - The Shanghai Composite Index closed at 3859.80 points, above the annual line, with a change of 0.52% [1] - The total trading volume of A-shares reached 14312.80 billion yuan [1] Stocks Breaking Annual Line - A total of 148 A-shares have surpassed the annual line today, with notable stocks including: - Tengda Technology with a deviation rate of 9.43% - Shengyang Technology at 9.02% - Jida Zhengyuan at 8.67% [1] - Stocks with smaller deviation rates that just crossed the annual line include *ST Biology, Hongte Technology, and Yunding Technology [1] Top Performers - The top three stocks with the highest deviation rates are: 1. Tengda Technology: Today's increase of 10.01%, turnover rate of 22.36%, latest price at 23.85 yuan [1] 2. Shengyang Technology: Today's increase of 10.00%, turnover rate of 6.20%, latest price at 12.10 yuan [1] 3. Jida Zhengyuan: Today's increase of 10.02%, turnover rate of 8.23%, latest price at 26.57 yuan [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Shengbang Safety with an increase of 8.32% and a deviation rate of 6.63% [1] - Pingmei Co. with an increase of 6.35% and a deviation rate of 5.95% [1] - Tianao Electronics with an increase of 10.00% and a deviation rate of 5.73% [1]

Core Viewpoint - The company is actively investing in innovative drug projects and exploring collaboration opportunities to expand its business in response to the growing market for innovative pharmaceuticals [2]. Group 1: Company Performance - As of October 17, 2025, the company's stock price closed at 5.6 yuan, reflecting a decrease of 1.93% with a turnover rate of 0.53% and a trading volume of 85,900 shares, resulting in a transaction amount of 48.68 million yuan [1]. Group 2: Investment and Innovation Strategy - The company has invested in several innovative drug and treatment projects through its subsidiary fund, focusing on areas such as HPV infection and liver cancer therapeutic vaccines, TCR-T cell therapy, and recombinant drugs, with some projects already in clinical stages and receiving government funding and investments from Hong Kong-listed companies [2]. - The company is closely monitoring domestic and international pharmaceutical industry trends and is leveraging its accumulated customer base, production capabilities, and technological advantages to seek opportunities for collaboration on innovative drug projects [2]. Group 3: Market Activity - On October 17, the net outflow of funds from major investors was 351,800 yuan, while speculative funds saw a net inflow of 1,111,500 yuan, and retail investors experienced a net outflow of 759,700 yuan [2].

Core Viewpoint - Haishang Pharmaceutical (002099) emphasizes its commitment to comply with the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding information disclosure [1] Group 1 - The company responded to investor inquiries on October 17, indicating adherence to legal and regulatory obligations [1] - Investors are encouraged to refer to the company's periodic reports and announcements for specific information [1]

Core Viewpoint - On October 9, Haixiang Pharmaceutical announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [1] Summary by Categories Company Actions - Haixiang Pharmaceutical has repurchased a total of 4,410,000 shares, which represents 0.27% of the company's total share capital [1]

Group 1 - Company HaiXiang Pharmaceutical announced a share buyback of 4.41 million shares, representing 0.27% of its total share capital, with a total transaction amount of approximately 26.09 million RMB [1] - The highest transaction price during the buyback was 6.29 RMB per share, while the lowest was 5.66 RMB per share [1] - As of the report, the market capitalization of HaiXiang Pharmaceutical is 9.5 billion RMB [1] Group 2 - For the first half of 2025, the revenue composition of HaiXiang Pharmaceutical is as follows: 65.89% from the pharmaceutical manufacturing sector, 33.09% from the dye industry, and 1.02% from other sources [1]